bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · IEX Real-Time Price · USD
0.899
-0.004 (-0.50%)
May 3, 2024, 3:36 PM EDT - Market open
bluebird bio Revenue
bluebird bio had revenue of $21.73M in the twelve months ending September 30, 2023, with 322.60% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $12.39M with 17,353.52% year-over-year growth. In the year 2022, bluebird bio had annual revenue of $3.60M, a decrease of -1.77%.
Revenue (ttm)
$21.73M
Revenue Growth
+322.60%
P/S Ratio
8.25
Revenue / Employee
$67,263
Employees
323
Market Cap
174.16M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 3.60M | -65.00K | -1.77% |
Dec 31, 2021 | 3.66M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 54.58M | 19.15M | 54.06% |
Dec 31, 2017 | 35.43M | 29.27M | 475.58% |
Dec 31, 2016 | 6.16M | -7.92M | -56.28% |
Dec 31, 2015 | 14.08M | -11.34M | -44.62% |
Dec 31, 2014 | 25.42M | 5.24M | 25.97% |
Dec 31, 2013 | 20.18M | 19.84M | 5,835.59% |
Dec 31, 2012 | 340.00K | -542.00K | -61.45% |
Dec 31, 2011 | 882.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Seres Therapeutics | 126.33M |
Harvard Bioscience | 112.25M |
Compugen | 33.46M |
MediWound | 18.69M |
Profound Medical | 5.41M |
BLUE News
- 3 hours ago - Lost Money on bluebird bio, Inc.(BLUE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - Accesswire
- 4 hours ago - Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming Deadline - Accesswire
- 5 hours ago - SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue - PRNewsWire
- 9 hours ago - Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact The Gross Law Firm - PRNewsWire
- 19 hours ago - bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 – BLUE - Accesswire
- 19 hours ago - DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm - Accesswire
- 1 day ago - Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact Levi & Korsinsky - Accesswire
- 1 day ago - Shareholders That Lost Money on bluebird bio, Inc.(BLUE) Should Contact Levi & Korsinsky About Pending Class Action - BLUE - Accesswire